IXC Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Invex Therapeutics Ltd

Watchlist Manager

Watchlist

Price on Oct 14: 0.115 AUD

Market Cap: AU$8.6m

Prices of ASX stocks are not being updated. The latest IXC price on Alpha Spread is from Oct 14, 2026. Financials, forecasts and intrinsic value keep updating.

	Invex Therapeutics Ltd ASX:IXC	AU

Profitability Summary

Invex Therapeutics Ltd's profitability score is 32/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Low Gross Margin

Low 3Y Average Gross Margin

Negative Operating Margin

-782%

Negative 3Y Average Operating Margin

-311%

Declining Operating Margin

-617% > -782%

Negative Net Margin

-772%

Negative 3Y Average Net Margin

-310%

Declining Net Margin

-617% > -772%

Negative Free Cash Flow Margin

-776%

Negative 3Y Average Free Cash Flow Margin

-328%

Declining Free Cash Flow Margin

-547% > -776%

Negative ROE

-30%

Negative 3Y Average ROE

Exceptional 3Y Average ROIC

1,777%

Declining ROIC

1,931% > 1,170%

View All

Hide

Collapse

32 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.